Trial Profile

A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Flulvesant Versus Placebo in Combination With Flulvesant in Previously Untreated HR-positive, HER2-negative Advanced Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2025 Results presented in the Sino Biopharmaceutical Media Release.
21 Oct 2025 According to a Sino Biopharmaceutical Media Release, data from this trial was presented at the European Society of Medical Oncology (ESMO) Congress 2025.
21 Oct 2025 Results presented in the Sino Biopharmaceutical Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com